Sorafenib tosylate in advanced kidney cancer: Past, present and future

Camillo Porta, Chiara Paglino, Ilaria Imarisio, Elisa Ferraris

Research output: Contribution to journalArticlepeer-review


The objective of this paper was to review the development of sorafenib tosylate in kidney cancer. The MedLine database, the Proceedings of the Annual American Society of Clinical Oncology meeting, as well as those of other key international meetings were extensively searched to identify relevant publications. Furthermore, the authors' direct experience with the drug was taken into account when commenting on the results retrieved. Sorafenib is a multikinase inhibitor that targets VEGF and PDGF receptors, other kinases, as well as the serine-threonine kinase Raf. Following early signs of activity from phase I and II studies, it has been shown to improve survival of pretreated advanced kidney cancer patients within a placebo-controlled, randomized, phase III trial, leading to its approval both in the United States and in Europe. Its activity has been subsequently confirmed in a real-world population by two expanded access programs performed globally, but not in a first-line setting; it also proved to be non-cross-resistant with two other molecularly targeted agents. Finally, its toxicity profile, which is acceptable and highly predictable, makes sorafenib appealing for combination treatments, especially with other molecularly targeted agents. Despite having been already demonstrated to be active in kidney cancer, the exact role of sorafenib in the first-line setting, in patients who have failed other molecularly targeted agents, and especially in combination with other agents, deserves further, prospective, studies.

Original languageEnglish
Pages (from-to)409-415
Number of pages7
JournalAnti-Cancer Drugs
Issue number6
Publication statusPublished - Jul 2009


  • Advanced disease
  • Kidney cancer
  • Sorafenib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Sorafenib tosylate in advanced kidney cancer: Past, present and future'. Together they form a unique fingerprint.

Cite this